Interventional Cardiology
Advertisement
AI is transforming cardiac imaging with faster diagnoses, better accuracy, and new insights into disease prediction.
Combining valve replacement and ATTR-CA drug therapy significantly improves survival in older adults with aortic stenosis.
GORE TAG TBE receives FDA nod for Zones 0–1, expanding minimally invasive repair options for aortic arch lesions.
ICMs detect AF in 29% of cryptogenic stroke patients, helping guide timely anticoagulation therapy.
Elective mitral valve-in-valve procedures are tied to lower 3-year mortality, a large study finds.
Physiologically significant lesions post-MI show more high-risk plaque features, per new PROSPECT II substudy findings.
OCT-derived virtual flow reserve predicts 2-year vessel failure post-PCI, adding physiologic insight to anatomic assessment.
OCTIVUS shows PCI outcomes improve with EAPCI-defined stent optimization, regardless of imaging modality.
LuX-Valve offers a safe, effective option for severe TR patients at high surgical risk.
Dr. Salman Allana shares key insights on how operator volume impacts retrograde CTO PCI success and outcomes.
Experts call for better trials and teamwork to advance transcatheter valve treatment for heart failure-related valve disease.
CTA-first screening before TAVR avoids invasive angiography in 53% of patients—without compromising outcomes.
Delays in TAVI for acute decompensated aortic stenosis worsen outcomes.
First surgical removal of a Harmony valve due to endocarditis reveals complex challenges and implications.
NAVULTRA registry compares Navitor vs. SAPIEN 3 Ultra in TAVR, revealing key tradeoffs in pacemaker use, PVL, and HF outcomes
The FDA approved the use of Edwards Lifesciences' SAPIEN 3 TAVR platform for patients with severe aortic stenosis.
Dr. Amit Goyal of the CardioNerds analyzed the BHF PROTECT-TAVI trial.
The REPAIR study offers the most comprehensive real-world assessment of outcomes after mitral TEER.
The ROLLER COASTR-EPIC22 trial is the first randomized head-to-head comparison of three plaque modification techniques.
Patients between the ages of 50 and 70 years with a mechanical heart valve have better long-term survival.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.